We would like to offer a different opinion on the ideas presented in the article by [@b6-ehp0115-a00014]. The authors indicated that their article summarized scientific literature published since an earlier U.S. Environmental Protection Agency (EPA) risk assessment of trichloroethylene (TCE), with an emphasis on the possible role of proliferator-activated receptor α (PPARα) agonism relevant to TCE risk assessment. Interestingly, in the section on recent data on PPARα agonism, Keshava and Caldwell failed to establish any gene expression signature relating TCE and PPARα.

[@b6-ehp0115-a00014] contended that it is difficult to identify a clear pattern of common gene expression changes for TCE and PPARα agonists in general. However, they did not consider numerous reports and reviews (e.g., [@b7-ehp0115-a00014]; [@b10-ehp0115-a00014]) illustrating that there are common and reproducible changes in gene expression associated with PPARα agonists. Further, extensive characterization has definitively demonstrated specific, direct targets of PPARα-retinoid X receptor heterodimers (reviewed by [@b7-ehp0115-a00014]). [@b6-ehp0115-a00014] also did not discuss the possibility that the effect of TCE on gene expression could be mediated by mechanisms independent of PPARα, which likely explains the disparity described in their article. Keshava and Caldwell did not critically discuss the data summarized in their Table 2 ([@b6-ehp0115-a00014]), failing to note that many of these gene targets have no clear linkage with the PPARα agonist mode of action (MOA) and may be mediated either via different ligand--receptor--coactivator complexes that form on the promoter regions of the regulated genes by secondary events downstream of the initial events associated with PPARα activation, or by mechanisms that are independent of PPARα. In addition, the authors failed to describe the limitations of the various gene array platforms and to correctly interpret the findings in the context of gene targets by other PPARα agonists, especially when more comprehensive data sets exist but were not cited ([@b2-ehp0115-a00014], [@b3-ehp0115-a00014]).

[@b6-ehp0115-a00014] further raised concerns regarding the use of PPARα-null mice to evaluate the MOA of PPARα by indicating that the physiologic differences observed in PPARα-null mice relative to wild-type mice suggest that the null mouse is an inadequate model to study the PPARα MOA. The data they cited, however, appears selective because they failed to mention that liver regeneration in PPARα-null mice is reportedly unchanged compared with wild-type mice ([@b11-ehp0115-a00014]), and age-related, sexually dimorphic obesity has not been observed in congenic PPARα-null mice ([@b1-ehp0115-a00014]). Thus, although the null mouse exhibits changes consistent with the critical role of PPARα in modulating fatty acid catabolism, this phenotype does not preclude its application for determining the critical role of this receptor in the MOA of PPARα agonists. Importantly, [@b6-ehp0115-a00014] did not comprehensively discuss significant findings *a*) that PPARα-null mice are refractory to liver tumors induced by two different PPARα agonists ([@b5-ehp0115-a00014]; [@b9-ehp0115-a00014]); *b*) that they are refractory to increased markers of replicative DNA synthesis and suppression of apoptosis after exposure to numerous PPARα ligands (summarized by [@b10-ehp0115-a00014]); or *c*) that PPARα-null mice expressing the human PPARα in the liver respond to PPARα agonists by increasing expression of genes encoding proteins that catabolize lipids, but they fail to show increases in markers of cell proliferation and are resistant to liver cancer ([@b4-ehp0115-a00014]; [@b8-ehp0115-a00014]). To dismiss these findings through lack of discussion or citation does little to advance our understanding and suggests that Keshava and Caldwell's article is unbalanced.

[@b6-ehp0115-a00014] also misrepresented an earlier review by [@b7-ehp0115-a00014] regarding the MOA of PPARα agonists. [@b6-ehp0115-a00014] incorrectly suggested that [@b7-ehp0115-a00014] placed substantial weight on the associative event of peroxisome proliferation with this MOA, when, in fact, peroxisome proliferation was strongly---but not causally---associated, as noted for sustained increased cell proliferation. [@b6-ehp0115-a00014] also misconstrued this review ([@b7-ehp0115-a00014]), focusing on DNA damage as a possible contributor to the MOA. Citing one manuscript that examined the effect of one, nonspecific PPARα ligand (DHEA) is not sufficient to refute the comprehensive review by [@b7-ehp0115-a00014]. Finally, [@b6-ehp0115-a00014] also suggested that the effects of PPARα ligands on mitochondrial function are part of the MOA, but they provided no direct evidence to support their contention that PPARα agonists or TCE causes mitochondrial dysfunction.

In summary, [@b6-ehp0115-a00014] missed an excellent opportunity to critically and objectively examine the data that support or refute the role of PPARα in TCE-induced effects. In our opinion, their article did not advance our understanding of the MOA of PPARα agonists or TCE.
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